07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq:ARVN), a biotechnology company creating a new class of drugs based on targeted protein ...
News
- Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast ...
- Capital Impact Advisors Has Upped Its Matador Res Co (MTDR) Stake; Meridian Bioscience (VIVO ...
Capital Impact Advisors Llc increased Matador Res Co (MTDR) stake by 28% reported in 2018Q2 SEC filing. Capital Impact Advisors Llc acquired ...
- Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event ...
The study results are being presented at the 2018 San Antonio Breast ... (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas. ... KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL.
- Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ...
... Subgroup in Phase III ExteNET Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium.
- Leaders in SA biotech, military medicine to meet in inaugural summit
Several of San Antonio's heavy hitters in bioscience plan to meet with their military counterparts in the Alamo City in an effort to develop deeper ...